Lung Cancer

The FDA grants fast track designation to VS-7375, an oral KRAS G12D dual ON/OFF inhibitor, advancing new hope for pretreated non–small cell lung cancer (NSCLC).

Seven-year CROWN trial update shows lorlatinib delivers durable progression-free survival and strong brain control in ALK-positive NSCLC.

At ASCO 2026, CHRYSALIS-2 data show amivantamab plus lazertinib extends survival in atypical EGFR-mutated NSCLC, reshaping first-line care.

Heavy marijuana smoking may increase lung cancer risk, with cannabis use disorder linked to higher odds of small cell and non–small cell disease.

Phase 1b data show zongertinib delivers durable first-line responses in HER2-mutant NSCLC, including brain metastases, with manageable safety.

A study finds that nearly half of older adults with mNSCLC do not receive treatment despite major advances in immunotherapy and targeted therapies that can improve survival and quality of life.

Advanced lung cancer inflammation index (ALI) predicts 3‑month recovery after thrombolysis for acute ischemic stroke, with low ALI signaling higher risk.

Oncology pharmacists should weigh lung cancer and diet data, probing pesticides as a possible factor in young nonsmokers.

Pharmacist lung cancer insights on NSCLC: biomarker testing, PD-1 choices like cemiplimab, and access tips for treating non small cell lung cancer.

COVID-19 infection may create lasting changes in the lung microenvironment—particularly through thymidine phosphorylase–driven pathways—that could increase the risk of lung cancer over time.

Keytruda Qlex is a subcutaneous formulation of pembrolizumab that offers a faster, more convenient alternative to IV administration with comparable efficacy.

Octogenarians with early-stage non–small cell lung cancer (NSCLC) can safely undergo surgery and achieve survival and quality-of-life outcomes comparable to those of younger patients.

New research identifies caspase-8 loss as a key driver of inflammatory reprogramming and tumor recurrence in small cell lung cancer.

Tarlatamab, a DLL3 T‑cell engager, advances treatment of extensive‑stage SCLC.

The approval is supported by findings from the phase 1 Beamion LUNG-1 clinical trial.

Circulating tumor cell PD-L1 liquid biopsy guides PD-1 therapy in lung cancer, helping oncology pharmacists predict response and monitor disease in real time.

Experts discuss the importance of optimizing immunotherapy for advanced NSCLC, enhancing treatment selection and patient care.

Pembrolizumab in adjuvant NSCLC therapy can trigger central adrenal insufficiency with vague fatigue, nausea, and hyponatremia.

The FDA approves a once-monthly dosing schedule for amivantamab and hyaluronidase-lpuj to optimize administration and cut down infusion times.

Amivantamab with lazertinib emerges as a promising frontline therapy for EGFR-mutated metastatic NSCLC, enhancing overall survival and treatment tolerability.

The phase 3 ADRIATIC trial demonstrates that consolidation durvalumab following concurrent chemoradiotherapy improves survival while maintaining health-related quality of life.

New research reveals circulating tumor cells can predict patient response to tarlatamab in small cell lung cancer, enhancing personalized treatment strategies.

New research reveals a gut bacteria-derived molecule that enhances lung cancer immunotherapy, potentially improving outcomes for patients with limited treatment options.

The role of cancer-associated fibroblasts in non–small cell lung cancer (NSCLC) drug resistance highlights innovative strategies to enhance treatment efficacy.

Researchers develop a novel therapy combining molecular glues and KRAS inhibitors, showing promise in treating KRAS-mutant non–small cell lung cancer.